← 產業報告目錄
Longevity and Anti-Senescence Therapy Market Size, Share & Trends Analysis Report By Therapy (Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, Others), By Application, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-25頁數 185報告編號 INSIGHTACE-fba7728924
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 2,736.43 million as of 2023, the global Longevity and Anti-Senescence Therapy Market is set to climb to USD 4,121.54 million by 2030, reflecting a compound annual growth rate of 6.8% over the 2024–2030 period.
At its core, Longevity and Anti-Senescence Therapy pertains to an effective approach focuses on the extension of health span by slowing the rate of aging. Stakeholders across the healthcare landscape are expandingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and expanding investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Longevity and Anti-Senescence Therapy Market Snapshot
Chapter 4. Global Longevity and Anti-Senescence Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Key Healthcare Companies
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Therapy Estimates & Trend Analysis
5.1. By Therapy & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapy:
5.2.1. Senolytic Drug Therapy
5.2.2. Gene Therapy
5.2.3. Cell Therapy
5.2.4. Mitochondrial Therapy
5.2.5. Immunotherapy
5.2.6. Others
Chapter 6. Market Segmentation 1: By Applications Estimates & Trend Analysis
6.1. By Applications & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Applications:
6.2.1. Longevity
6.2.2. Senescence Inhibition
6.2.3. Cardiovascular Diseases
6.2.4. Neural Degenerative Diseases
6.2.5. Ophthalmology Disorders
6.2.6. Cancer
Chapter 7. Longevity and Anti-Senescence Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Therapy, 2024-2031
7.1.2. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Applications, 2024-2031
7.1.3. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.2.2. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.2.3. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.3.2. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.3.3. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million), 2024-2031
7.4.2. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.4.3. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million) 2024-2031
7.5.2. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.5.3. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Acorda Therapeutics
8.2.2. Agex Therapeutics
8.2.3. Antoxerene
8.2.4. Calico Life Sciences
8.2.5. Celgene
8.2.6. Cleara Biotech
8.2.7. Human Longevity Inc.
8.2.8. Insilico Medicine
8.2.9. Oisin Biotechnology
8.2.10. Powervision Inc.
8.2.11. Prana Biotechnology Ltd.
8.2.12. Proteostasis Therapeutics Inc.
8.2.13. Recursion Pharmaceuticals
8.2.14. Restorbio
8.2.15. Sierra Sciences Llc
8.2.16. Senex Biotechnology
8.2.17. Senolytic Therapeutics
8.2.18. Spotlight Bioscience
8.2.19. T.A. Sciences
8.2.20. Unity Biotechnology
8.2.21. Alkahest, Inc.
8.2.22. Stealth BioTherapeutics
8.2.23. BIOPHYTIS BSA
8.2.24. SIWA Therapeutics
8.2.25. Rejuveron Life Sciences AG
8.2.26. Rubedo Life Sciences, Inc
8.2.27. Lineage Cell Therapeutics
8.2.28. Juvenescence Life
8.2.29. Longevity Biotech CohBar, Inc. (CWBR)
8.2.30. Genome Protection Inc.
8.2.31. Navitor Pharmaceuticals, Inc.
8.2.32. Elevian, Inc.
8.2.33. Velabs Therapeutics
8.2.34. Other Prominent Player
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們